| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Chemomab Therapeutics Ltd. | CM-101 | Liver Fibrosis | Phase 2a | Ongoing | Intravenous | Gastroenterology |
| Chemomab Therapeutics Ltd. | CM-101 - (ABATE) | Systemic Sclerosis | Phase 2 | Trial Discontinued | Intravenous | Immunology |
| Chimerix Inc. | IV Brincidofovir | Adult allo-HCT recipients with Adenovirus | Phase 2 | Trial Discontinued | Intravenous | Immunosuppressant |
| Chimerix Inc. | DSTAT | Acute lung injury (ALI) in COVID-19 | Phase 2 | Trial Discontinued | Intravenous | COVID-19 |
| Chimerix Inc. | Oral Brincidofovir - AdAPT Study | Allogeneic hematopoietic stem cell transplant (HCT) recipients with adenovirus (AdV) | Phase 2 | Trial Discontinued | Oral | Immunosuppressant |
| Cingulate Inc. | CTx-1301 (fixed dose, pediatric study) | ADHD | PDUFA | Ongoing | Oral | Psychiatric |
| Cingulate Inc. | CTx-1301 (dexmethlyphenidate HCI) | ADHD in patients six years of age or older | NDA Filing | Ongoing | oral | Psychiatric |
| Cingulate Inc. | CTx-1301 (dexmethlyphenidate HCI) | ADHD in patients six years of age or older | NDA Filing | Ongoing | oral | Psychiatric |